Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis https://t.co/64dsA63F53

Les médicaments modificateurs de la maladie pour les personnes présentant une première crise clinique suggérant un… https://t.co/By9A45LsHF

Low-quality evidence suggests small and uncertain benefit with early treatment for MS. No safety data https://t.co/3XQSq0P8uN

@eurims https://t.co/CEU2yMyIoF

Low-quality #CochraneEvidence: poss small, uncertain benefit of early treatment w/ disease-modifying drugs for #MS: https://t.co/I2TRdIPDkk

@rincondesisifo Seguridad y eficacia de fármacos modificadores de la enfermedad en pac con esclerosis múltiple https://t.co/BXdTFurme5…via @rincondesisifo

(Cochrane) Seguridad y eficacia de los fármacos modificadores de la enfermedad en pac con esclerosis múltiple https://t.co/Qfh4o7VI5F

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. https://t.co/zQPzeuiEcA

CochraneLibrary: Disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis https://t.co/9w2E6jNE9J https://t.co/ilhfYbPLEa

Cochrane review on benefit & safety of the approved DMTs for treatment of a first clinical attack suggestive of #MS https://t.co/YmyMQpkgvD

Treatment with disease-modifying drugs for people with a first clinical attack suggestive… https://t.co/h9CT6T092a

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. https://t.co/dqQm8GEncc